Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada
Provided By GlobeNewswire
Last update: May 8, 2025
– Esperion to Receive an Upfront Payment, Near-Term Milestones and Tiered Royalties on Product Sales –
– Further Expands Global Access to Bempedoic Acid Products and Provides Opportunity to Bring Innovative Preventative Therapy to 2.6 million Canadians Living with Diagnosed Heart Disease –
Read more at globenewswire.com
